Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EmoLED is a Class IIa medical device developed by Emoled Srl that utilizes blue light photobiomodulation (wavelength 400-430 nm) to accelerate the healing of chronic wounds, including stage II and III pressure ulcers. The 'silver-EmoLED' protocol refers to a combination therapy where the EmoLED device is used as an adjuvant to standard wound care that includes topical silver agents, such as ionic silver spray powder or hyaluronic acid sodium salt with metallic silver. The blue light therapy works by interacting with endogenous photoreceptors like mitochondrial cytochrome c oxidase to modulate inflammation and stimulate tissue repair. The silver component provides broad-spectrum antimicrobial activity to manage the wound bioburden, preventing or treating infection in the ulcerated area. This combination has been evaluated in clinical studies like the RISE_UP trial to verify its effectiveness in supporting the reparative process of decubitus lesions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on silver + EmoLED.